您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

顏毅豪醫師

病毒性肝炎診治、肝硬化肝衰竭診治、肝癌藥物治療
  • 國語,英語,閩南語
  • 助理教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院胃腸肝膽科系副教授級主治醫師(2019.07)
    • 長庚大學兼任助理教授
  • 學歷
    • 高雄醫學大學 醫學系畢
    • 長庚大學 臨床醫學研究所碩士班畢
  • 經歷
    • 屏東基督教醫院內科住院醫師
    • 高雄長庚醫院內科住院醫師
    • 高雄長庚醫院胃腸肝膽科總醫師
    • 縣立鳳山醫院委託高雄長庚醫院經營 胃腸肝膽科主治醫師
    • 高雄長庚紀念醫院 胃腸肝膽科系副系主任(2020.07-2023.06)
  • 學會與認證
    • 台灣內科醫學會內科專科醫師及指導醫師
    • 台灣消化系醫學會消化系內科專科醫師
    • 台灣消化系內視鏡醫學會消化系內視鏡專科醫師
    • 台灣肝癌醫學會專科醫師
    • 台灣腫瘤消融學會認證肝腫瘤消融手術醫師
    • 台灣醫學教育學會一般醫學師資
  • 論文及期刊發表
    • Li WF, Moi SH, Liu YW, Lin CC, Yong CC, Wang CC*, Yen YH*, Lin CY. A preoperative model to predict overall survival in patients with hepatoma undergoing resection. Am J Surg. 2024 Nov:237:115778. (SCI) 待登錄
      術前預測細胞癌病患接受手術切除的整體存活率
    • Yen YH*, Liu YW(co-first), Li WF, Yong CC, Wang CC*, Lin CY. A simple model to predict early recurrence of hepatocellular carcinoma after liver resection. Langenbecks Arch Surg. 2024 Aug 23;409(1):261. (SCI)
      一個簡單的模式可以預測肝細胞癌病患接受手術切除發生早期復發
    • Yen YH*, Kuo FY(Co-first), Eng HL, Liu YW, Yong CC, Wang CC*, Li WF, Lin CY. Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes. Updates Surg. 2024 Jun;76(3):879-887. (SCI)
      非酒精性脂肪肝相關的肝細胞癌病患接受手術切除其預後和病毒性肝炎相關的肝細胞癌病患相近
    • Yen YH*, Kee KM, Hu TH, Tsai MC, Kuo YH, Li WF, Liu YW, Wang CC*, Lin CY. Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies. PLoS One. 2024 Mar 15;19(3):e0290523. (SCI)
      B型肝炎相關的肝細胞癌有較好的整體存活率
    • Li WF, Moi SH, Liu YW, Yong CC, Wang CC*, Yen YH*, Lin CY. Using the hazard function to evaluate hepatocellular carcinoma recurrence risk after curative resection. Updates Surg. 2023 Dec;75(8):2147-2155. (SCI)
      使用風險功能來評估肝細胞癌病患接受手術切除的復發機率
    • Yen YH*, Kuo FY(Co-first), Eng HL, Liu YW, Yong CC, Li WF, Wang CC*, Lin CY. Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma. PLoS One. 2023 Nov 16;18(11):e0292144. (SCI)
      腫瘤壞死可以預測肝癌病患接受手術切除後發生早期復發
    • Yen YH*, Li WF(Co-first), Liu YW, Yong CC, Wang CC*, Lin CY. A simple preoperative model to predict overall survival of patients undergoing liver resection for hepatocellular carcinoma ≧10 cm. HPB (Oxford). 2023 Nov;25(11):1373-1381. (SCI)
      一種簡單的術前預測模式用來預測肝細胞癌病患腫瘤大於10公分接受手術切除的整體存活率
    • Liu YW, Moi SH, Li WF, Lin CC, Yong CC, Wang CC*, Yen YH*, Lin CY. A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma. Eur J Surg Oncol. 2023 Aug;49(8):1444-1449. (非SCI)
      單顆肝細胞癌病患接受手術切除一術前預測模式用來預測早期復發
    • Li WF, Liu YW, Wang CC*, Yong CC, Lin CC, Yen YH*. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages. Langenbecks Arch Surg. 2023 May 1;408(1):169. (SCI)
      肝細胞癌病患接受手術切除影像上的腫瘤負荷分數可以用來預測整體存活率在不同的巴塞隆納期別
    • Liu YW, Li WF, Kuo FY, Eng HL, Wang CC*, Lin CC, Yong CC, Yen YH*. Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer. Langenbecks Arch Surg. 2023 Apr 27;408(1):166. (SCI)
      第8版的美國癌症聯合委員會T1a和T1b的肝癌病患接受手術切除後的整體存活率沒有差別
    • Yen YH*, Kee KM, Li WF, Liu YW, Wang CC*, Hu TH, Tsai MC, Kuo YH, Lin CY. Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. Cancers (Basel). 2023 Mar 9;15(6):1687. (SCI)
      肝細胞癌病患的死因在不同的慢性肝病之間的差異
    • Kuo FY, Eng HL, Li WF, Liu YW, Wang CC*, Lin CC, Yong CC, Yen YH*. Tumor Necrosis Is an Indicator of Poor Prognosis Among Hepatoma Patients Undergoing Resection. J Surg Res. 2023 Mar;283:1091-1099. (SCI)
      腫瘤壞死是肝癌病患接受手術切除預後不好的預測因子
    • Li WF, Liu YW, Wang CC*, Yong CC, Lin CC, Yen YH*. Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of ≦ 2 cm. PLoS One. 2023 Feb 9;18(2):e0281154. (SCI)
      顯微鏡下的血管侵犯可能和肝癌病患單顆腫瘤小於2公分接受手術切除的存活無關
    • Yen YH*, Liu YW, Li WF, Wang CC*, Yong CC, Lin CC, Lin CY. Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma. Cancers. 2023 Feb;15(4):1203. (SCI)
      甲型胎兒蛋白合併影像的腫瘤體積分數可以預測肝癌病患接受手術切除的存活
    • Yen YH*, Kee KM, Li WF, Liu YW, Wang CC*, Hu TH, Tsai MC, Lin CY. Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. Cancers. 2023 Feb;15(4):1222. (SCI)
      在台灣的肝癌病患甲型胎兒蛋白升高的趨勢是穩定的
    • Yen YH*, Li WF, Kee KM, Wang CC*, Cheng YF, Lu SN, Hung CH, Liu YW, Hu TH. Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. Langenbecks Arch Surg. 2023 Jan 7;408(1):12. (SCI)
      7公分是合適的切點用來預測預後在單顆肝癌病患
    • Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg. 2022 Aug;74(4):1345-1352. (SCI)
      驗證一胎兒蛋白預測模式在預測肝癌病患接受手術切除後復發
    • Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC. Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort. Updates Surg. 2022 Jun;74(3):891-897. (SCI)
      手術前的預測因子用來預測早期肝癌病患接受手術切除後發生不可換肝的肝癌復發:應用在一個東亞族群
    • Liu YW, Yen YH*(co-first), Li WF, Wang CC*, Lu SN, Kee KM, Yong CC, Cheng YF, Wang JH, Hu TH, Hung CH, Chen CH. Minimally invasive surgery versus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma: Results from a high-volume liver surgery center in East Asia. Surg Oncol. 2022 Jun;42:101769. (SCI)
      比較微創手術和射頻燒融治療早期肝癌:一東亞大型肝臟手術中心的經驗報告
    • Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg. 2022 May;223(5):945-950. (SCI)
      術前的影像及胎兒蛋白可以預測肝癌病患接受手術切除後早期復發
    • Yen YH*, Li WF(co-first), Kee KM, Wang CC*, Cheng YF, Wang JH, Lu SN, Hung CH. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbecks Arch Surg. 2022 Feb;407(1):225-234. (SCI)
      肝癌病患合併巨觀下血管侵犯:東西方病患間的特徵的比較
    • Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY*, Cheng YF, Wang JH, Yen YH*, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg. 2022 Feb;223(2):339-345. (SCI)
      大顆的分化良好肝癌接受手術切除其臨床病理特徵及預後
    • Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Liver resection in elderly patients with hepatocellular carcinoma: age does matter. Updates Surg. 2021 Aug;73(4):1371-1380. (SCI)
      年紀大於75歲的肝癌病患接受手術切除整體存活率較差
    • Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival. Updates Surg. 2021 Apr;73(2):399-409. (SCI)
      肝癌病患接受手術切除根據復發後的存活率以6個月做為定義早期復發
    • Yen YH*, Cheng YF, Wang JH, Lin CC, Chen CH, Wang CC. Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS One. 2021 Mar 25;16(3):e0249194. (SCI)
      遵循修改過的巴塞隆納肝癌分期治療指引:一個東亞大型肝臟手術中心的結果報告
    • Yen YH*, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One. 2021 Jan 13;16(1): e0244939. (SCI)
      肝癌發生在無肝硬化病患的臨床表徵及病因:東西方的比較
    • Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol. 2021 Jan;123(1):222-235. (SCI)
      肝癌合併顯微鏡下的門靜脈侵犯是一個重要的預後因子在手術切除肝癌病患
    • Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*, Chen CH. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. J Surg Oncol. 2020 Dec ;122(8):1587-1594. (SCI)
      手術切除肝癌在巴塞隆納肝癌治療指引建議與不建議手術切除肝癌的預後分析:一東亞大型肝臟手術中心結果報告
    • Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Wang JH, Yen YH*. Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center. PLoS One. 2020 Mar 27;15(3):e0230897. (SCI)
      單顆大型肝癌手術切除預後分析:一個亞洲大型肝臟手術醫學中心的結果
    • Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH*. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One. 2020 Mar 12;15(3):e0230005. (SCI)
      比較東西方在臨床治療後期肝癌的差異
    • Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH*. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One. 2019 Oct 3;14(10):e0222605. (SCI)
      未治療完全的肝癌和C肝全口服新藥治療失敗有關
    • Yen YH, Kuo FY, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice. Medicine (Baltimore). 2019 Jul;98(27):e16270. (SCI)
      真實世界使用超音波診斷肝硬化在慢性C肝病患具有高特異性
    • Yen YH, Hu TH*. Reply to the Letter to the Editor regarding Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: More questions than answer? J Formos Med Assoc. 2019 Jan;118(1 Pt 3):537-538. (SCI)
      回覆給編輯的信: 身體質量指數增加是一個和肝硬化相關的危險因子
    • Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis. 2019 Jan;51(1):142-148. (SCI)
      慢性C型肝炎糖尿病和嚴重纖維化以及纖維化惡化有關
    • Yen YH, Kee KM, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One. 2019 Jan 9;14(1):e0208858. (SCI)
      持續性病毒反應與代謝因子和慢性C型肝炎病患死亡有關
    • Yen YH, Kuo FY, Lin CC, Chen CL, Chang KC, Tsai MC, Hu TH*. Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. Transplant Proc. 2018 Dec;50(10):3533-3538. (SCI)

    • Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. Medicine (Baltimore). 2018 Dec;97(50):e13383. (SCI)

    • Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, Hu TH*. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. J Formos Med Assoc. 2018 Sep;117(9):833-840. (SCI)

    • Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018 Jun 28;13(6):e0199760. doi: 10.1371/journal.pone.0199760.

    • Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018 Jun;38(6):1064-1073. (SCI)

    • Yen YH, Hu TH*. Reply to the letters to the editor regarding the elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: Methodological issues. J Formos Med Assoc. 2018 Apr;117(4):352.

    • Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, Lin JT, Hu TH*, Wang JH, Chen CH. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formos Med Assoc. 2018 Apr;117(4):268-275.

    • Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, Tsai MC, Lin JT, Hu TH*. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc. 2017 Nov;116(11):852-861. (SCI)

    • Huang CM, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH*. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS One. 2017 Aug 10;12(8):e0182204. (SCI)

    • Yen YH, Chen JB*, Cheng BC, Chen JF, Chang KC, Tseng PL, Wu CK, Tsai MC, Lin MT, Hu TH*. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study. PLoS One. 2017 Apr 20;12(4):e0176027. (SCI)

    • Cheng BC#, Yen YH#(co-first), Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB*, Hu TH*. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep. 2017 Apr 19;7:46458. (SCI)

    • Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH*. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep. 2016 Sep 26;6:33816.

    • Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH*. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol. 2016 Jul 25;16(1):73. (SCI)

    • Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH*. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. J Formos Med Assoc. 2016 Jun;115(6):440-4. (SCI)

    • Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC*, Lee CM*. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. J Formos Med Assoc. 2015 Jul;114(7):652-8. (SCI)

    • Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN*. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009 Jun;41(6):431-41. (SCI)

    • Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, Lu SN, Lee CM*. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008 Jan 1;27(1):72-9. (SCI)

    • Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int. 2007 Dec;27(10):1349-55. (SCI)

    • Yen YH, Wang JH, Lu SN, Chen TY, Changchien CS, Chen CH, Hung CH, Lee CM. Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol. 2006 Dec;60(3):439-44. (SCI)

    • Yen YH, Wang JH, Hung CH, Chen CH, Tseng PL, Lu SN. Gastric ulcer triggered after percutaneous ethanol injection therapy for left lobe hepatocellular carcinoma. Liver Int. 2006 May;26(4):502-3. (SCI)

    • Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, Lu SN. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int. 2005 Dec;25(6):1162-8. (SCI)

    • Yen YH, Wang JH, Lu SN, Changchien CS. Contrast-enhanced ultrasonography in hepatic angiomyolipoma. J Ultrasound Med. 2005 Jun;24(6):855-9. (SCI)